Mike MacKinnon, Chief Executive Officer
Mike MacKinnon joins ROX from Philips North America where he was Head of Sales for Image Guided Technologies, Devices. He joined Philips through the acquisition of Volcano where he was General Manager of Phoenix Atherectomy and Peripheral Sales Leader. In 2014 Volcano acquired AtheroMed, where Mike was President and CEO. Prior to AtheroMed, Mr. MacKinnon held various leadership positions with Hansen Medical, Access Closure and FoxHollow Technologies. Mike earned his BS in marketing and Legal Studies from University of Massachusetts at Lowell.
Rodney Brenneman, Founder & Chief Technology Officer
Rodney Brenneman has 24 years of experience in the medical device industry. He co-founded ROX Medical in 2004. Prior to ROX Medical Mr. Brenneman worked for USGI Medical as Vice President of R&D. At USGI he led a team of nine engineers and technicians to develop devices for endo-luminal GI surgery. Mr. Brenneman co-founded TheraCardia in 1998 and served as VP of R&D and Operations until 2003. Prior to 1998, Mr. Brenneman worked for Vesica Medical, acquired by Boston Scientific, Corp in 1996 and Advanced Surgical Intervention acquired by Boston Scientific, Corp in 1993. Mr. Brenneman has also done considerable consulting for very early stage medical device companies in a wide variety of specialties including Cardiology, Orthopedics, Urology, Opthamology, Neurology and Interventional Radiology.
Jonathan Sackner-Bernstein, MD, Chief Medical Officer and Executive VP of Clinical and Regulatory Affairs
Jonathan Sackner-Bernstein is the Chief Medical Officer and Executive Vice President of Clinical and Regulatory Affairs. Dr. Sackner-Bernstein’s expertise in medical product development leverages his broad and deep experience as cardiologist, clinical investigator, regulator and product development. He has consulted for a wide range of biotechnology and medical device companies, as well as serving as Associate Center Director in the Center for Devices and Radiological Health at FDA. Previously Dr. Sackner-Bernstein led the clinical and regulatory groups for NeoStem, which included financial, regulatory, clinical and operational oversight of a 61-site Phase II trial of stem cell therapy.
Paul Sobotka, MD, Chief Scientific Officer
Paul Alan Sobotka, M.D., F.A.C.C., F.A.C.P., F.A.H.A., Chief Medical Officer of ROX, Inc. Graduated from Stanford University with degree in Chemistry and obtained his Medical Degree from the University of Illinois College of Medicine. Dr. Sobotka completed training in Internal Medicine at The University of Michigan, followed by specialty training in cardiovascular diseases at Northwestern University. He holds an appointment as Clinical Professor of Medicine/Cardiology at The Ohio State University.
Dr. Sobotka has authored nearly 200 peer reviewed manuscripts and book chapters including manuscripts published in: The Journal Clinical Investigation, American Journal of Physiology, The New England Journal of Medicine, Circulation: The Lancet, Circulation: Heart Failure, Journal of Congestive Failure, Hypertension, Journal of Hypertension, Journal of the American Society of Nephrology, and Journal of Congestive Heart Failure.
Peter Balmforth, Director of Therapy Development, Education, and Sales
Peter Balmforth is the Director of Therapy Development, Education and Sales for Europe. Bringing 10 years of medical device experience, Peter joined ROX Medical in 2010 to lead the European market. Prior to ROX, he was Country Manager for both Atritech and Ablation Frontiers, both exited in successful mergers with BSX and Medtronic. Previously he served as Territory Manager for Endocardial Solutions, Inc., and post acquisition by St. Jude Medical, he continued his service as Product Manager.
Chris Yelley, Director of Operations
Chris Yelley is the Director of Operations for ROX Medical. With over 30 years of experience in the medical device industry Chris joined ROX Medical in 2008 to lead the manufacturing and operations efforts. Prior to joining ROX Medical Chris was with ev3 Neurovascular where he led the Process Development team. From 2000 through 2005 Chris served as Vice President of Operations with IntraLuminal Therapeutics in Carlsbad, CA. He has lead operations, quality, engineering and manufacturing teams both nationally and internationally, developing lean and efficient processes and programs for, MRI Interventions, Intravascular Research Limited and Advanced Cardiovascular Systems (Guidant).